Vaccine Billing Audits at the Pharmacy Counter

Every immunization encounter at the pharmacy counter generates two billing lines, and PBM audit teams test both during flu, COVID-19, and RSV season claims review. The administration fee, billed on a CPT code such as 90471 or a Medicare HCPCS code such as G0008, compensates the pharmacist for the injection. The vaccine product bills on its own separate code. Behind both claims sits a third record auditors pull first: the consent, screening, lot number, and NDC documentation for that dose. A gap in any one becomes a recoupment finding that repeats across the full lookback period once extrapolation applies.

Administration Fee and Product Are Two Separate Claims

CPT 90471 reports administration of one injectable vaccine, billed separately from the vaccine itself. CPT 90460 and 90461 apply when the patient is 18 or younger and the encounter includes counseling. Medicare uses its own administration-only codes, G0008 for influenza, G0009 for pneumococcal, and G0010 for hepatitis B, each required to pair with the product code administered and the Z23 diagnosis code on the same claim. Submitting an administration code without its paired product code, or the reverse, is among the most common reasons a payor denies or later recoups a vaccine claim.

PREP Act Authority Has a Defined Scope and an End Date

The federal PREP Act declaration, most recently extended by HHS's Twelfth Amendment published in the Federal Register on December 11, 2024, authorizes licensed pharmacists, pharmacy interns, and qualified pharmacy technicians to order and administer COVID-19 vaccines, and to administer seasonal influenza vaccine to patients ages 3 through 18, through December 31, 2029. The declaration can preempt narrower state scope-of-practice rules for those two vaccine categories specifically. It does not authorize every immunization a pharmacy offers: RSV vaccination and adult influenza administration outside that declaration run on each state's pharmacy practice act. An audit or licensing review checks the vaccine, the patient's age, and the date of service against whichever authorization actually applied.

Consent and Screening Records

Federal law requires vaccine providers to furnish the applicable CDC Vaccine Information Statement before each dose of a vaccine covered by the National Childhood Vaccine Injury Act, 42 U.S.C. § 300aa-26, and to record in the patient's file which VIS edition was given and the date. CDC guidance is explicit that a VIS is not an informed consent form. Most states layer a separate consent requirement on top of it. A pre-administration screening questionnaire documenting contraindications and precautions is standard CDC practice guidance. Auditors treat a missing screening form, an unsigned consent record, or a VIS edition mismatch as a documentation failure, and bill it as an overpayment regardless of whether the correct vaccine was given.

Lot Number, NDC, and Expiration Records

CDC guidance on documenting vaccine NDCs and lot numbers flags a structural problem: manufacturers package vaccines with one NDC and lot number on the unit-of-sale carton and a different one on the unit-of-use vial or syringe actually administered, and most pharmacy systems store only a single field for each. When the claim number does not match the purchase invoice, PBM auditors treat the mismatch as an overpayment even when the correct product was given. Expiration date verification at the point of administration closes the same gap.

A vaccine claim can be clinically correct and still fail a PBM audit if the consent record, the lot number, or the administration code does not match what the file requires.

When a Vaccine Billing Finding Escalates

A single flagged vaccine claim rarely ends a PBM audit alone. A pattern across a flu, COVID-19, or RSV season, projected through extrapolation over the lookback period, converts a documentation gap into a six-figure recoupment demand and, in the more severe cases, a network termination. Pharmacies contesting a vaccine-billing finding should review our companion pieces on signature log findings in pharmacy audits, what a PBM audit actually costs, and the Prime Therapeutics audit process, since the audit appeal deadlines described there apply equally to vaccine-claim findings.

Why Early Legal Counsel Is Critical

It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a PBM audit notice or other government inquiry involving vaccine claims. Early legal intervention can protect the pharmacy's rights, ensure the response addresses the administration billing, consent, and lot documentation at issue, avoid inadvertent admissions, and preserve defenses that may otherwise be lost. Delaying representation can significantly affect the outcome of the audit.

How Health Law Alliance Can Help

Health Law Alliance defends pharmacies nationwide in PBM audits, including findings built on vaccine administration billing, consent documentation, and lot number discrepancies. Our bench includes a former federal prosecutor, background that shapes how we evaluate which flagged vaccine claims are defensible. If your pharmacy has received an audit notice involving immunization billing, contact us for a free, confidential consultation.